(Total Views: 3941)
Posted On: 05/05/2017 1:21:00 PM
Post# of 1460
AVXL just meandering around here, a bit under 6. NTRP flat-lining at 8.55, which actually is an improvement over the trades in the 6's that we saw.
NTRP is a classic example of a botched data release of a study that was rushed. Had they let it run to the 6 months which would have been meaningful as a comparison to other Alzheimer's drugs, the stock price might be a very different story.
Impatience kills. I hope the company continues this study so we get some idea whether this pathway is a good one to pursue -- whether it's NTRP or some other company that does it.
NTRP is a classic example of a botched data release of a study that was rushed. Had they let it run to the 6 months which would have been meaningful as a comparison to other Alzheimer's drugs, the stock price might be a very different story.
Impatience kills. I hope the company continues this study so we get some idea whether this pathway is a good one to pursue -- whether it's NTRP or some other company that does it.
(0)
(0)
